vs
Side-by-side financial comparison of CAMDEN NATIONAL CORP (CAC) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.
CAMDEN NATIONAL CORP is the larger business by last-quarter revenue ($64.3M vs $37.2M, roughly 1.7× GYRE THERAPEUTICS, INC.). CAMDEN NATIONAL CORP runs the higher net margin — 34.0% vs -3.7%, a 37.7% gap on every dollar of revenue. Over the past eight quarters, CAMDEN NATIONAL CORP's revenue compounded faster (22.6% CAGR vs 17.0%).
Camden National Bank is a commercial bank headquartered in Camden, Maine, operating as the principal subsidiary of Camden National Corporation, a publicly traded bank holding company. Founded in 1875, the bank became a direct, wholly owned subsidiary of the holding company following a corporate reorganization in 1984. Following the 2025 merger with Northway Financial, the combined institution has approximately $7.0 billion in assets.
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
CAC vs GYRE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $64.3M | $37.2M |
| Net Profit | $21.9M | $-1.4M |
| Gross Margin | — | 95.3% |
| Operating Margin | — | 0.3% |
| Net Margin | 34.0% | -3.7% |
| Revenue YoY | — | 33.4% |
| Net Profit YoY | — | -340.1% |
| EPS (diluted) | $1.29 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $64.3M | — | ||
| Q4 25 | $68.1M | $37.2M | ||
| Q3 25 | $65.4M | $30.6M | ||
| Q2 25 | $62.3M | $26.8M | ||
| Q1 25 | $60.1M | $22.1M | ||
| Q4 24 | $47.6M | $27.9M | ||
| Q3 24 | $45.0M | $25.5M | ||
| Q2 24 | $42.8M | $25.2M |
| Q1 26 | $21.9M | — | ||
| Q4 25 | $22.6M | $-1.4M | ||
| Q3 25 | $21.2M | $5.9M | ||
| Q2 25 | $14.1M | $1.6M | ||
| Q1 25 | $7.3M | $3.7M | ||
| Q4 24 | $14.7M | $569.0K | ||
| Q3 24 | $13.1M | $2.9M | ||
| Q2 24 | $12.0M | $4.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 95.3% | ||
| Q3 25 | — | 94.7% | ||
| Q2 25 | — | 95.7% | ||
| Q1 25 | — | 95.9% | ||
| Q4 24 | — | 95.8% | ||
| Q3 24 | — | 96.2% | ||
| Q2 24 | — | 96.9% |
| Q1 26 | — | — | ||
| Q4 25 | 41.5% | 0.3% | ||
| Q3 25 | 40.5% | 22.7% | ||
| Q2 25 | 28.5% | 8.1% | ||
| Q1 25 | 10.3% | 10.3% | ||
| Q4 24 | 38.7% | 2.4% | ||
| Q3 24 | 35.2% | 16.6% | ||
| Q2 24 | 34.7% | 12.7% |
| Q1 26 | 34.0% | — | ||
| Q4 25 | 33.1% | -3.7% | ||
| Q3 25 | 32.4% | 19.4% | ||
| Q2 25 | 22.6% | 5.9% | ||
| Q1 25 | 12.2% | 16.9% | ||
| Q4 24 | 30.8% | 2.0% | ||
| Q3 24 | 29.1% | 11.2% | ||
| Q2 24 | 28.0% | 18.0% |
| Q1 26 | $1.29 | — | ||
| Q4 25 | $1.33 | $-0.01 | ||
| Q3 25 | $1.25 | $0.03 | ||
| Q2 25 | $0.83 | $0.00 | ||
| Q1 25 | $0.43 | $0.00 | ||
| Q4 24 | $1.00 | $0.00 | ||
| Q3 24 | $0.90 | $0.01 | ||
| Q2 24 | $0.81 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $52.4M |
| Total DebtLower is stronger | $514.4M | — |
| Stockholders' EquityBook value | $710.0M | $106.0M |
| Total Assets | $7.0B | $166.1M |
| Debt / EquityLower = less leverage | 0.72× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $52.4M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $54.4M | ||
| Q1 25 | — | $29.9M | ||
| Q4 24 | — | $26.7M | ||
| Q3 24 | — | $25.1M | ||
| Q2 24 | — | $25.1M |
| Q1 26 | $514.4M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $710.0M | — | ||
| Q4 25 | $696.6M | $106.0M | ||
| Q3 25 | $676.4M | $101.9M | ||
| Q2 25 | $652.1M | $92.0M | ||
| Q1 25 | $640.1M | $68.1M | ||
| Q4 24 | $531.2M | $63.3M | ||
| Q3 24 | $529.9M | $63.2M | ||
| Q2 24 | $508.3M | $60.4M |
| Q1 26 | $7.0B | — | ||
| Q4 25 | $7.0B | $166.1M | ||
| Q3 25 | $7.0B | $159.4M | ||
| Q2 25 | $6.9B | $152.6M | ||
| Q1 25 | $7.0B | $129.8M | ||
| Q4 24 | $5.8B | $125.4M | ||
| Q3 24 | $5.7B | $125.2M | ||
| Q2 24 | $5.7B | $120.9M |
| Q1 26 | 0.72× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-5.6M |
| Free Cash FlowOCF − Capex | — | $-5.8M |
| FCF MarginFCF / Revenue | — | -15.5% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-180.0K |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $63.9M | $-5.6M | ||
| Q3 25 | $36.1M | $4.7M | ||
| Q2 25 | $6.0M | $2.1M | ||
| Q1 25 | $1.0M | $-129.0K | ||
| Q4 24 | $60.9M | $-2.8M | ||
| Q3 24 | $-14.5M | $1.7M | ||
| Q2 24 | $14.5M | $-5.5M |
| Q1 26 | — | — | ||
| Q4 25 | $58.2M | $-5.8M | ||
| Q3 25 | $35.4M | $4.0M | ||
| Q2 25 | $4.5M | $1.8M | ||
| Q1 25 | $-727.0K | $-251.0K | ||
| Q4 24 | $55.4M | $-2.8M | ||
| Q3 24 | $-16.2M | $1.0M | ||
| Q2 24 | $13.2M | $-6.9M |
| Q1 26 | — | — | ||
| Q4 25 | 85.5% | -15.5% | ||
| Q3 25 | 54.1% | 13.1% | ||
| Q2 25 | 7.3% | 6.8% | ||
| Q1 25 | -1.2% | -1.1% | ||
| Q4 24 | 116.4% | -10.1% | ||
| Q3 24 | -36.0% | 4.1% | ||
| Q2 24 | 30.8% | -27.5% |
| Q1 26 | — | — | ||
| Q4 25 | 8.4% | 0.4% | ||
| Q3 25 | 1.1% | 2.2% | ||
| Q2 25 | 2.4% | 1.0% | ||
| Q1 25 | 2.9% | 0.6% | ||
| Q4 24 | 11.7% | 0.2% | ||
| Q3 24 | 3.8% | 2.7% | ||
| Q2 24 | 3.0% | 5.8% |
| Q1 26 | — | — | ||
| Q4 25 | 2.83× | — | ||
| Q3 25 | 1.70× | 0.79× | ||
| Q2 25 | 0.43× | 1.32× | ||
| Q1 25 | 0.14× | -0.03× | ||
| Q4 24 | 4.15× | -4.85× | ||
| Q3 24 | -1.11× | 0.60× | ||
| Q2 24 | 1.21× | -1.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CAC
| Net Interest Income | $52.4M | 81% |
| Noninterest Income | $12.0M | 19% |
GYRE
Segment breakdown not available.
